

01-25-2002



To the Hon. Commissioner of Patents and Trademarks Please record the attached original or copy thereof Docket No. JG-HK-5040 / 500572.20032		101959543
SUBMISSION TYPE: <input checked="" type="checkbox"/> New <input type="checkbox"/> Resubmission (Non-Recordation) Document ID # <input type="checkbox"/> Correction of PTO Error / Reel # / Frame # <input type="checkbox"/> Corrective Document / Reel # / Frame #		Nature or Conveyance: <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Change of Name <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Other: EXECUTION DATE: November 1, 2001
Name of conveying Party(ies): Saburo SAKODA (50%)		Execution Date(s) (M / D / Y): November 1, 2001
Name of receiving Party(ies): Kyorin Pharmaceutical Co., Ltd. Address of receiving Party(ies): 5, Kanda Surugadai 2-chome, Chiyoda-ku, Tokyo 101-0062, JAPAN If document to be recorded is an assignment and the receiving party is not domiciled in the United States, an appointment of a domestic representative designation is attached: <input type="checkbox"/> YES <input type="checkbox"/> NO (DESIGNATIONS MUST BE A SEPARATE DOCUMENT FROM ASSIGNMENT)		
Correspondence and/or Domestic Representative Name, Address and Phone No.: Jules E. Goldberg, Esq., Reed Smith LLP, 375 Park Avenue, New York, NY 10152 [Tel. No. (212)521-5400]		
DO NOT USE THIS SPACE		
Pages Enter the total number of pages of the attached conveyance document including any attachments: [2]		
Application number(s) or Patent number(s): Enter either the patent Application Number or the Patent Number (DO NOT ENTER BOTH NUMBERS for the same property) A) Application number(s): 09/762,616 B) Patent number(s):		
If this document is being filed together with a New Application, enter the date the patent application was signed by the first named executing inventor (M/D/Y):		
Patent Cooperation Treaty (PCT)		
Number of Properties Enter the total number of properties involved: [1]		
Fee Amount Fee Amount for Properties Listed (37 CFR 3.41): \$40.00 Method of payment: <input checked="" type="checkbox"/> Enclosed <input type="checkbox"/> Deposit Account (The Commissioner is hereby authorized to charge the deposit account any additional fees required or to credit any overpayment to Deposit Account No: 50-1529.) Deposit Account Enter for payment by deposit account or if additional fees can be charge to the account. Deposit Account Number: 50-1529 Authorization to charge additional fees <input type="checkbox"/> Yes <input type="checkbox"/> No		
Statement and Signature To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. Charges to deposit account are authorized, as indicated herein. <div style="display: flex; justify-content: space-between;"> <div> Jules E. Goldberg Reg. No.: 24,408 Name of Person Signing </div> <div style="text-align: center;"> Signature </div> <div> Date: December 6, 2001 </div> </div>		
MAILING CERTIFICATE I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box ASSIGNMENTS, Patent and Trademarks Office, Washington, DC 20231 on December 6, 2001 <div style="display: flex; justify-content: space-between;"> <div> / Ruth Montalvo </div> </div>		

01/25/2002 LMUELLER 00000067 09762616

01 FC:581

40.00 OP

**ASSIGNMENT - PATENT APPLICATION
UNITED STATES OF AMERICA**

Whereas, I, Saburo Sakoda of Osaka University Medical School, 2-2, Yamdaoka, Suita-shi, Osaka 565-0871, Japan (hereafter "Assignor") have invented certain new and useful improvements in MEDICINE FOR MULTIPLE SCLEROSIS which application for Letters Patent in the United States of America has been filed.

And Whereas Kyorin Pharmaceutical Co., Ltd. of 5, Kanda Surugadai 2-chome, Chiyoda-Ku, Tokyo, 101-0062, Japan (hereinafter "Assignee") is desirous of acquiring an interest therein and in the Letters Patent to be obtained therefor:


Now, therefore, be it known by all whom it may concern, that for good and valuable consideration (the sufficiency of which is hereby acknowledged) the Assignor has assigned, transferred and set over, and by these presents does assign, transfer and set over unto the said Assignee for the territory of the United States of America, a fifty percent (50%) undivided interest in and to the said application and the invention embodied therein, as fully set forth and described in the specification filed in the U.S. Patent and Trademark Office under Application No. 09/762,616 on February 8, 2001 including any division, continuation, substitute or renewal application thereof; said invention, application and Letters Patent to be held and enjoyed by Saburo Sakoda and Kyorin Pharmaceutical Co., Ltd. to the full end of the term for which said Letters Patent is granted, as fully and entirely as the same would have been held by the Assignor had this assignment and transfer not been made.


Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks to issue any and all such Letters Patent for said invention to Saburo Sakoda and Kyorin Pharmaceutical Co., Ltd., each as a 50% undivided owner.

In testimony whereof, the Assignor has hereunto set his hand this 1st day of November, 2001.

WITNESS:

INVENTOR:


Koji Niibe


Saburo Sakoda